Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
COVID challenge studies estimated at £8-10m and these are still to come, No wonder a new clinic will be needed.
Thanks Barwickman, and apologies all about being a plank about the wearables. I always read the RNS’s but obviously not all the way to the bottom!
Cracking company, looking forward to Cathal’s next presentation.
Well ORPH continue to deliver on their promises, refreshing in this market....
Thompi, that info in editors notes has been in the last 6 RNS,s there just to say what’s going on and what’s happened, I’m sure we will get the official RNS on wearables if it works and the big boys want it, GL.
And in the Notes to Editors more about wearables -
“ hVIVO has built up one of the world's largest databases of infectious disease progression data and we are populating our Open Orphan Health Data platform with this historical hVIVO data. In our clinical trials going forward, we are also planning to collect data on volunteer's via wearables during clinical trials. Therefore, Open Orphan's data, which may yield valuable digital biomarkers, could be one of the more sought-after datasets by many of the large wearables /smart watch wearables providers around the world.
QU booked out until Dec 2021 with CONVENTIONAL studies. Covid bookings yet to come on top!
Quote:
With this contract, we are close to having the hVIVO quarantine clinic block booked with our conventional challenge studies until December 2021
Month-on-month locking in SP value.
Open Orphan.... pleased to announce a new £4.3 million contract to conduct a human viral challenge study utilising one of our 8 traditional challenge study models for another of the global top 10 vaccine companies.